Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus abiraterone in high-risk metastatic hormone-sensitive prostate cancer
CTR20221666Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib in prostate adenocarcinoma, prostate cancer (PCa), sponsored by Eli Lilly and Company. Started Jul 2022; status: terminated.
02
Drugs
abemaciclib
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20221666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221666.